Lynavoy (linerixibat) / Alfasigma 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lynavoy (linerixibat) / Alfasigma
LLSAT, NCT04167358 / 2023-503465-33-00 / 2019-003158-10 / CTR20222331: Linerixibat Long-term Safety, and Tolerability Study

Active, not recruiting
3
242
Europe, Canada, Japan, US, RoW
1. Chinese Generic Name: GSK2330672_Tablet; English Generic Name: GSK2330672_Tablet; Trade Name: NA; 2. Chinese Generic Name: GSK2330672_Tablet; English Generic Name: GSK2330672_Tablet; Trade Name: NA;
GlaxoSmithKline, GSK Pharma R&D
Indications: For cholestasis and pruritus in patients with primary biliary cholangitis (PBC).
09/26
09/26
2019-003158-10: Linerixibat Long-term Safety and Tolerability Study

Ongoing
3
305
Europe
linerixibat (GSK2330672) 45mg, GSK2330672, Tablet
GlaxoSmithKline Research & Development Ltd, GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT, GlaxoSmithKline LLC, GlaxoSmithKline Research & Development Limited
Moderate to Severe Pruritus (itching) caused by primary biliary cholangitis (PBC), Moderate to Severe Pruritus (itching) caused by primary biliary cholangitis (PBC), Diseases [C] - Digestive System Diseases [C06]
 
 
GLISTEN, NCT04950127 / 2021-000007-21 / CTR20212220: Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC)

Completed
3
238
Europe, Canada, Japan, US, RoW
Linerixibat, Placebo
GlaxoSmithKline
Pruritus
10/24
12/24
CTR20212220: A global study evaluating the efficacy and safety of linerixibat in treating pruritus in PBC participants.

Completed
3
35
China
1. Generic Chinese Name: GSK2330672_Tablet; Generic English Name: GSK2330672_Tablet; Trade Name: NA; 2. Generic Chinese Name: GSK2330672_Tablet; Generic English Name: GSK2330672_Tablet; Trade Name: NA; 3. Generic Chinese Name: GSK2330672_Placebo_Tablet; Generic English Name: GSK2330672_Placebo_Tablet; Trade Name: NA
GlaxoSmithKline (Ireland) Limited / Glaxo Operations UK Ltd (trading as Glaxo Wellcome Operations) / GlaxoSmithKline (China) Investment Co., Ltd.
Indications: For the treatment of cholestasis and pruritus in patients with primary biliary cholangitis (PBC).
 
 
212358, 2023-503465-33-00: Ph 3a, linerixibat, Long term safety and tolerability study in pts with PBC

Recruiting
2/3
82
Europe
Glaxosmithkline Research & Development Limited, GSK Pharma R&D
Cholestasis
 
 
NCT05448170: Linerixibat Compassionate Use for Cholestatic Pruritus Adult Patients With Primary Biliary Cholangitis (PBC)

Available
N/A
NA
Linerixibat
GlaxoSmithKline
Pruritus
 
 

Download Options